3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1
1
Status
Active not recruiting
3
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gastrointestinal
3
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Stomach Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Lung Neoplasms
2
Adenocarcinoma Of Esophagus
2
Urothelial Bladder Carcinoma
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Solid Tumor
1
Sarcoma
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Liver Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Advanced Non-Small Cell Lung Cancer
1
Interventions
Oxaliplatin
21
pembrolizumab
17
Capecitabine
15
Nivolumab
13
Paclitaxel
12
Fluorouracil
12
Leucovorin
11
Docetaxel
10
atezolizumab
7
Trastuzumab
7
tislelizumab
5
Ramucirumab
5
durvalumab
4
Standard of Care
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
Cisplatin
4
Carboplatin
4
zolbetuximab
3
zimberelimab
3
apatinib
3
Specimen Handling
3
S 1 (combination)
3
Gemcitabine
3
Bevacizumab
3
trifluridine tipiracil drug combination
2
tremelimumab
2
trastuzumab deruxtecan
2
relatlimab
2
osimertinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Active not recruiting
×
Stomach Neoplasms
×
zimberelimab
×
Clear all
NCT05891171
2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1
Active not recruiting
40 enrolled
NCT05329766
2026-06-02
EDGE-Gastric
Arcus Biosciences, Inc.
Phase 2
Active not recruiting
332 enrolled
NCT05568095
2026-06-02
STAR-221
Arcus Biosciences, Inc.
Phase 3
Active not recruiting
1,040 enrolled